Supercharging TIL Therapy with LNP-Based Neoantigen Vaccines: A New Era in Cancer Immunotherapy
Time: 1:45 pm
day: Conference Day One
Details:
- Developing cutting-edge lipid-based delivery systems designed to specifically activate T-cells through polyepitope vaccines designed to enhance immune responses against common malignancies
- Providing ‘Signal 1’ — precise T cell receptor binding — to trigger T cell proliferation, persistence, and tumor penetration to ensure effective cytotoxic activity against cancer cells
- Accelerating the time from bench to bedside for personalized T-cell therapeutics through rapid formulation techniques, enabling a swift immune response and enhancing therapeutic potency for cancer patient
